<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00879814</url>
  </required_header>
  <id_info>
    <org_study_id>6108A1-1004</org_study_id>
    <secondary_id>B1971004</secondary_id>
    <nct_id>NCT00879814</nct_id>
  </id_info>
  <brief_title>Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults</brief_title>
  <official_title>A Phase 1 Randomized, Open-label, Parallel-group, Active- And Placebo-controlled Study To Assess Safety And Tolerability Of 60, 120, And 200 Mcg Meningococcal Group B Rlp2086 Vaccine In Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of an investigational
      meningococcal B rLP2086 vaccine in healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With at Least One Adverse Event (AE)</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Alanine Aminotransferase [ALT])</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Aspartate Aminotransferase [AST])</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Total Protein)</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Albumin)</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Alkaline Phosphatase [ALP])</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Total Bilirubin)</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Creatine Phosphokinase [CPK])</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Prothrombin Time [PT])</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Partial Thromboplastin Time [PTT])</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Fibrinogen)</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Hemoglobin)</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (White Blood Cell [WBC])</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Lymphocytes)</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Neutrophils)</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Eosinophils)</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Platelet Count)</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Sodium).</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Potassium).</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Blood Urea Nitrogen [BUN]).</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Serum Creatinine).</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Red Blood Cells [RBC]).</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Protein).</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Glucose).</measure>
    <time_frame>Baseline up to Month 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Meningococcal Immunoglobulin G (IgG) Geometric Mean Titers (GMT)</measure>
    <time_frame>Before Dose 1, 1 month after Dose 2, before Dose 3, 1 month after Dose 3</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Meningitis, Meningococcal</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rLP2086 vaccine 60 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rLP2086 vaccine 120 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rLP2086 vaccine 200 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tdap vaccine - normal saline - normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rLP2086 vaccine or control</intervention_name>
    <description>intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rLP2086 vaccine or control</intervention_name>
    <description>intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rLP2086 vaccine or control</intervention_name>
    <description>intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rLP2086 vaccine or control</intervention_name>
    <description>intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A subject must meet the following inclusion criteria at screening (visit 1) and at
        randomization (visit 2) to be considered for enrollment in the study:

          -  Male or female subjects between the ages of 18 and 40.

          -  Healthy male or female subjects as determined by medical history, physical
             examination, and judgment of the investigator.

          -  Male or female subject who is considered biologically capable of having children must
             agree to commit to the use of a reliable method of birth control for the duration of
             the study and for 30 days after early discontinuation. A subject is still biologically
             capable of having children, even if he or she is using contraceptives or if his or her
             sexual partner is sterile or using contraceptives.

        In addition a subject must meet the following inclusion criteria at randomization (visit 2)
        to be considered for enrollment in the study. The referred blood and urinalysis tests
        (inclusion criterion 5) will be performed on a blood and urine sample taken at visit 1:

          -  Female subjects of childbearing potential with a negative urine pregnancy test prior
             to study drug administration. Note: this criterion will apply to each vaccination
             visit and to the last study visit.

          -  Laboratory blood and urinalysis tests results within the per-protocol normal ranges.

          -  Able to be contacted by telephone during the study period. Note: this criterion will
             apply to each study visit.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miami Research Associates, Inc.</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=6108A1-1004&amp;StudyName=Study%20Evaluating%20Safety%20And%20Tolerability%20Of%20Meningococcal%20B%20Rlp2086%20Vaccine%20In%20Healthy%20Adults</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2009</study_first_submitted>
  <study_first_submitted_qc>April 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2009</study_first_posted>
  <results_first_submitted>November 17, 2014</results_first_submitted>
  <results_first_submitted_qc>November 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2014</results_first_posted>
  <last_update_submitted>July 15, 2015</last_update_submitted>
  <last_update_submitted_qc>July 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of the 189 participants who signed informed consent form, 134 were screen failures (mainly because of laboratory abnormalities) and 7 participants withdrew before the first vaccination. Total 48 participants were randomized into 4 groups.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>rLP2086 60mcg</title>
          <description>Given on a 0, 2-, 6- month schedule</description>
        </group>
        <group group_id="P2">
          <title>rLP2086 120 mcg</title>
          <description>Given on a 0, 2-, 6- month schedule</description>
        </group>
        <group group_id="P3">
          <title>rLP2086 200 mcg</title>
          <description>Given on a 0, 2-, 6- month schedule</description>
        </group>
        <group group_id="P4">
          <title>Tdap/Normal Saline (Control)</title>
          <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Failed to Return</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all randomized participants who received at least 1 vaccination.</population>
      <group_list>
        <group group_id="B1">
          <title>rLP2086 60mcg</title>
          <description>Given on a 0, 2-, 6- month schedule</description>
        </group>
        <group group_id="B2">
          <title>rLP2086 120 mcg</title>
          <description>Given on a 0, 2-, 6- month schedule</description>
        </group>
        <group group_id="B3">
          <title>rLP2086 200 mcg</title>
          <description>Given on a 0, 2-, 6- month schedule</description>
        </group>
        <group group_id="B4">
          <title>Tdap/Normal Saline (Control)</title>
          <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.3" spread="7.40"/>
                    <measurement group_id="B2" value="31.0" spread="7.65"/>
                    <measurement group_id="B3" value="27.8" spread="6.05"/>
                    <measurement group_id="B4" value="27.2" spread="5.77"/>
                    <measurement group_id="B5" value="28.8" spread="6.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least One Adverse Event (AE)</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Adverse Event (AE)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7"/>
                    <measurement group_id="O2" value="91.7"/>
                    <measurement group_id="O3" value="91.7"/>
                    <measurement group_id="O4" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Alanine Aminotransferase [ALT])</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Alanine Aminotransferase [ALT])</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="91.7"/>
                    <measurement group_id="O3" value="83.3"/>
                    <measurement group_id="O4" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Aspartate Aminotransferase [AST])</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Aspartate Aminotransferase [AST])</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="91.7"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Total Protein)</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Total Protein)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Normal,Post Baseline:Mild/Moderate/Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Albumin)</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Albumin)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Normal,Post Baseline:Mild/Moderate/Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Alkaline Phosphatase [ALP])</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Alkaline Phosphatase [ALP])</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="91.7"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Total Bilirubin)</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Total Bilirubin)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="91.7"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Creatine Phosphokinase [CPK])</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Creatine Phosphokinase [CPK])</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="91.7"/>
                    <measurement group_id="O3" value="91.7"/>
                    <measurement group_id="O4" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8.3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Prothrombin Time [PT])</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Prothrombin Time [PT])</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="91.7"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8.3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Partial Thromboplastin Time [PTT])</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Partial Thromboplastin Time [PTT])</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Fibrinogen)</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Fibrinogen)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="41.7"/>
                    <measurement group_id="O4" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Mild+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Moderate+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Mild-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Hemoglobin)</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Hemoglobin)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="83.3"/>
                    <measurement group_id="O3" value="83.3"/>
                    <measurement group_id="O4" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (White Blood Cell [WBC])</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (White Blood Cell [WBC])</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7"/>
                    <measurement group_id="O2" value="83.3"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Mild+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Moderate+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8.3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Mild-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Lymphocytes)</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Lymphocytes)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="91.7"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8.3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Neutrophils)</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Neutrophils)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Eosinophils)</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Eosinophils)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="91.7"/>
                    <measurement group_id="O3" value="91.7"/>
                    <measurement group_id="O4" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="8.3"/>
                    <measurement group_id="O4" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Platelet Count)</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Platelet Count)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Normal,Post Baseline:Mild/Moderate/Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Sodium).</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Sodium).</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="91.7"/>
                    <measurement group_id="O3" value="91.7"/>
                    <measurement group_id="O4" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Mild+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Moderate+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Severe+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8.3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Grade 4 increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Potassium).</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Potassium).</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Mild+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Grade 4 increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Blood Urea Nitrogen [BUN]).</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Blood Urea Nitrogen [BUN]).</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Normal,Post Baseline:Mild/Moderate/Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Serum Creatinine).</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Serum Creatinine).</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Normal,Post Baseline:Mild/Moderate/Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Red Blood Cells [RBC]).</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Red Blood Cells [RBC]).</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="75.0"/>
                    <measurement group_id="O4" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Protein).</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Protein).</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="58.3"/>
                    <measurement group_id="O4" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Normal, Post-Baseline: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Glucose).</title>
        <time_frame>Baseline up to Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Glucose).</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Normal, Post-Baseline: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Normal,Post Baseline:Mild/Moderate/Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Meningococcal Immunoglobulin G (IgG) Geometric Mean Titers (GMT)</title>
        <time_frame>Before Dose 1, 1 month after Dose 2, before Dose 3, 1 month after Dose 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rLP2086 60mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 120 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 200 mcg</title>
            <description>Given on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O4">
            <title>Tdap/Normal Saline (Control)</title>
            <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Meningococcal Immunoglobulin G (IgG) Geometric Mean Titers (GMT)</title>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subfamily A: Before Dose 1 (N=12, 12, 12, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="6.3" upper_limit="47.8"/>
                    <measurement group_id="O2" value="16.8" lower_limit="6.4" upper_limit="43.6"/>
                    <measurement group_id="O3" value="7.5" lower_limit="3.1" upper_limit="17.8"/>
                    <measurement group_id="O4" value="7.9" lower_limit="3.4" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subfamily A: 1 Month After Dose2 (N=10, 12, 11, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1522.7" lower_limit="817.5" upper_limit="2836.0"/>
                    <measurement group_id="O2" value="1933.5" lower_limit="1036.3" upper_limit="3607.6"/>
                    <measurement group_id="O3" value="1132.7" lower_limit="575.0" upper_limit="2231.1"/>
                    <measurement group_id="O4" value="3.1" lower_limit="1.7" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subfamily A: Before Dose 3 (N=10, 11, 11, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495.7" lower_limit="238.0" upper_limit="1032.4"/>
                    <measurement group_id="O2" value="500.7" lower_limit="253.6" upper_limit="988.7"/>
                    <measurement group_id="O3" value="318.6" lower_limit="147.4" upper_limit="688.5"/>
                    <measurement group_id="O4" value="3.5" lower_limit="1.6" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subfamily A: 1 Month After Dose 3 (N=8, 10, 9, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4107.4" lower_limit="1752.3" upper_limit="9627.6"/>
                    <measurement group_id="O2" value="4326.9" lower_limit="2214.5" upper_limit="8454.2"/>
                    <measurement group_id="O3" value="2664.8" lower_limit="1410.8" upper_limit="5033.4"/>
                    <measurement group_id="O4" value="3.8" lower_limit="2.1" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subfamily B: Before Dose 1 (N=12, 12, 12, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="6.1" upper_limit="40.2"/>
                    <measurement group_id="O2" value="7.1" lower_limit="2.9" upper_limit="17.5"/>
                    <measurement group_id="O3" value="8.8" lower_limit="4.0" upper_limit="19.5"/>
                    <measurement group_id="O4" value="5.1" lower_limit="2.2" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subfamily B: 1 Month After Dose2 (N=10, 12, 11, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="850.5" lower_limit="547.1" upper_limit="1322.2"/>
                    <measurement group_id="O2" value="1071.2" lower_limit="641.4" upper_limit="1789.0"/>
                    <measurement group_id="O3" value="1300.9" lower_limit="692.5" upper_limit="2443.6"/>
                    <measurement group_id="O4" value="2.8" lower_limit="1.1" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subfamily B: Before Dose3 (N=10, 11, 11, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289.8" lower_limit="168.0" upper_limit="499.8"/>
                    <measurement group_id="O2" value="361.4" lower_limit="192.7" upper_limit="677.6"/>
                    <measurement group_id="O3" value="370.2" lower_limit="145.7" upper_limit="940.6"/>
                    <measurement group_id="O4" value="3.1" lower_limit="1.1" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subfamily B: 1 Month After dose 3 (N=8, 10, 9, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2081.9" lower_limit="1098.1" upper_limit="3947.1"/>
                    <measurement group_id="O2" value="2295.3" lower_limit="1224.2" upper_limit="4303.5"/>
                    <measurement group_id="O3" value="3445.0" lower_limit="1544.9" upper_limit="7682.2"/>
                    <measurement group_id="O4" value="2.6" lower_limit="1.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Month 7</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>rLP2086 60mcg</title>
          <description>Given on a 0, 2-, 6- month schedule</description>
        </group>
        <group group_id="E2">
          <title>rLP2086 120 mcg</title>
          <description>Given on a 0, 2-, 6- month schedule</description>
        </group>
        <group group_id="E3">
          <title>rLP2086 200 mcg</title>
          <description>Given on a 0, 2-, 6- month schedule</description>
        </group>
        <group group_id="E4">
          <title>Tdap/Normal Saline (Control)</title>
          <description>Tdap was given at month 0 and Saline was given at Month 2 and 6</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood fibrinogen decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood fibrinogen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mean cell haemoglobin concentration decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mean cell haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Protein urine</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Red blood cells urine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Red cell distribution width increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

